Clinical-stage genetic-medicines company for neurological diseases.
| Date | Round | Amount |
|---|---|---|
| Jun 2024 | Series B Vico Therapeutics, a Leiden genetic-medicines biotech, raised a EUR11.5M Series B second close from Seroba and Kurma Partners. | $12.4M |
| Jan 2024 | Series B Vico Therapeutics, a Leiden genetic-medicines biotech, raised a EUR54M Series B led by Ackermans & van Haaren. | $58M |